Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor

Figures & data

Table 1 The major visual acuity outcomes of the Basheer et al¹ study compared with those from three pivotal ranibizumab trials

Visual outcomes	Present study	CATT trial^2	ANCHOR trial^4	MARINA trial^3
12 months
Maintained vision: loss of <15	91.8	96.0	96.4	94.6
ETDRS letters (% of eyes)		(P=0.03)	(P=0.03)	(P=0.24)
Improved vision: gain of ≥15	20.3	25.0	40.3	33.8
ETDRS letters (% of eyes)		(P=0.25)	(P=0.00004)	(P=0.003)
24 months
Maintained vision: loss of <15	88.6	93.0	89.9	90.0
ETDRS letters (% of eyes)		(P=0.08)	(P=0.64)	(P=0.65)
Improved vision: gain of ≥15	19.7	33.0	41.0	35.0
ETDRS letters (% of eyes)		(P=0.002)	(P=0.00001)	(P=0.0007)

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.